Transgene (France) Performance
| TNG Stock | EUR 0.73 0.02 2.82% |
The entity has a beta of 0.0049, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Transgene's returns are expected to increase less than the market. However, during the bear market, the loss of holding Transgene is expected to be smaller as well. At this point, Transgene SA has a negative expected return of -0.54%. Please make sure to validate Transgene's skewness, day typical price, and the relationship between the maximum drawdown and daily balance of power , to decide if Transgene SA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Transgene SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's technical and fundamental indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 5.3 M | |
| Total Cashflows From Investing Activities | 16.8 M |
Transgene |
Transgene Relative Risk vs. Return Landscape
If you would invest 107.00 in Transgene SA on September 5, 2024 and sell it today you would lose (34.00) from holding Transgene SA or give up 31.78% of portfolio value over 90 days. Transgene SA is producing return of less than zero assuming 3.1714% volatility of returns over the 90 days investment horizon. Simply put, 28% of all stocks have less volatile historical return distribution than Transgene, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Transgene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Transgene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Transgene SA, and traders can use it to determine the average amount a Transgene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1718
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TNG |
Estimated Market Risk
| 3.17 actual daily | 28 72% of assets are more volatile |
Expected Return
| -0.54 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Transgene is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Transgene by adding Transgene to a well-diversified portfolio.
Transgene Fundamentals Growth
Transgene Stock prices reflect investors' perceptions of the future prospects and financial health of Transgene, and Transgene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Transgene Stock performance.
| Return On Equity | -0.36 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (1.27) % | |||
| Operating Margin | (1.39) % | |||
| Current Valuation | 144.73 M | |||
| Shares Outstanding | 100.2 M | |||
| Price To Earning | 18.08 X | |||
| Price To Book | 3.39 X | |||
| Price To Sales | 10.07 X | |||
| Revenue | 9.99 M | |||
| EBITDA | (16.55 M) | |||
| Cash And Equivalents | 16.9 M | |||
| Cash Per Share | 0.27 X | |||
| Debt To Equity | 162.30 % | |||
| Book Value Per Share | 0.55 X | |||
| Cash Flow From Operations | (31.94 M) | |||
| Earnings Per Share | (0.23) X | |||
| Total Asset | 101.84 M | |||
| Retained Earnings | (538 M) | |||
| Current Asset | 51 M | |||
| Current Liabilities | 27 M | |||
About Transgene Performance
By analyzing Transgene's fundamental ratios, stakeholders can gain valuable insights into Transgene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Transgene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Transgene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. TRANSGENE operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 132 people.Things to note about Transgene SA performance evaluation
Checking the ongoing alerts about Transgene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Transgene SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Transgene SA generated a negative expected return over the last 90 days | |
| Transgene SA has some characteristics of a very speculative penny stock | |
| Transgene SA has high historical volatility and very poor performance | |
| Transgene SA has a very high chance of going through financial distress in the upcoming years | |
| Transgene SA has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the revenue of 9.99 M. Net Loss for the year was (19.54 M) with loss before overhead, payroll, taxes, and interest of (15.87 M). | |
| Transgene SA has accumulated about 16.9 M in cash with (31.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27. |
- Analyzing Transgene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Transgene's stock is overvalued or undervalued compared to its peers.
- Examining Transgene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Transgene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Transgene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Transgene's stock. These opinions can provide insight into Transgene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Transgene Stock analysis
When running Transgene's price analysis, check to measure Transgene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transgene is operating at the current time. Most of Transgene's value examination focuses on studying past and present price action to predict the probability of Transgene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transgene's price. Additionally, you may evaluate how the addition of Transgene to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |